| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CYP2D6; CYP2DL1; Cytochrome P450 2D6; CYPIID6; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase |
| Entrez GeneID | 1565 |
| WB Predicted band size | Calculated MW: 56 kDa; Observed MW: 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Recombinant protein of human CYP2D6 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Cytochrome P450 2D6(CYP2D6)抗体的3篇参考文献示例，涵盖抗体的开发、验证及应用研究：
---
1. **文献名称**：*"Development and Characterization of a Monoclonal Antibody Specific for Human Cytochrome P450 2D6"*
**作者**：Matsunaga T, et al.
**摘要**：本研究报道了一种针对人CYP2D6的单克隆抗体的开发，并验证了其在Western blot和免疫组化中的特异性。抗体成功区分了CYP2D6与其他P450亚型，可用于检测肝组织和细胞系中CYP2D6的蛋白表达水平。
---
2. **文献名称**：*"Interindividual Variation in CYP2D6 Protein Expression: Correlation with Genetic Polymorphisms and Clinical Implications"*
**作者**：Gaedigk A, et al.
**摘要**：通过结合基因分型和免疫分析法(使用CYP2D6特异性抗体)，本研究揭示了CYP2D6蛋白表达的个体差异与基因多态性的关联。结果显示，某些功能缺失突变导致蛋白表达显著降低，为个体化用药提供了实验依据。
---
3. **文献名称**：*"Quantitative Analysis of CYP2D6 in Human Liver Microsomes by Immunoblotting: Impact of Sample Preparation and Antibody Selection"*
**作者**：Hanioka N, et al.
**摘要**：研究评估了不同抗体对CYP2D6定量的影响，比较了多种商业化抗体的灵敏度和特异性。提出优化样本处理流程以提高检测准确性，并强调抗体选择对药物代谢研究的重要性。
---
(注：以上文献信息为示例，若需实际文献，建议通过PubMed或Google Scholar检索关键词“CYP2D6 antibody”获取近年研究。)
Cytochrome P450 2D6 (CYP2D6) is a key enzyme in the cytochrome P450 superfamily, primarily involved in the metabolism of approximately 20-25% of clinically used drugs, including antidepressants, antipsychotics, beta-blockers, and opioids. Genetic polymorphisms in the CYP2D6 gene result in significant interindividual variability in enzyme activity, categorizing individuals as poor, intermediate, normal, or ultrarapid metabolizers. This variability impacts drug efficacy, toxicity, and dosing requirements, making CYP2D6 a critical focus in pharmacogenetics and personalized medicine.
CYP2D6 antibodies are immunodetection tools developed to study the expression, localization, and function of this enzyme. These antibodies are typically generated using recombinant CYP2D6 proteins or synthetic peptides as immunogens, followed by purification and validation for specificity. They enable researchers to quantify CYP2D6 protein levels in tissues (e.g., liver, brain) via techniques like Western blotting, immunohistochemistry, or immunofluorescence. Such studies help elucidate tissue-specific expression patterns, genetic or regulatory influences on enzyme activity, and interactions with drugs or environmental factors.
In clinical and research settings, CYP2D6 antibodies also aid in phenotyping studies to correlate genotype with metabolic phenotype, assess drug-drug interactions, or investigate CYP2D6's role in diseases like cancer or neurological disorders. However, challenges remain, including cross-reactivity with other CYP isoforms and variability in antibody performance across experimental platforms, necessitating rigorous validation. Overall, CYP2D6 antibodies are vital for advancing drug development, toxicology, and precision medicine initiatives.
×
